A Review on Applications of Artificial Intelligence (AI) in Parkinsons’s Disease Diagnosis and Treatment and Its Future Challenges

Year : 2025 | Volume : 15 | Issue : 03 | Page : 1 15
    By

    Gazal Rani,

  1. Research Scholar, Department of Engineering and Technology, Chitkara University, Rajpura, Punjab, India

Abstract

Parkinson’s disease (PD) is a long-term, progressive neurodegenerative disorder that mainly occurs in people older than 60 years, affecting nearly 1% of this population. It is chiefly marked by the loss of dopaminergic neurons in the substantia nigra, a crucial brain region responsible for controlling motor functions. The resultant dopamine deficiency significantly disrupts motor control, manifesting in clinical symptoms such as tremors, bradykinesia, muscle rigidity, and postural instability. While PD severely impacts patients’ quality of life, early detection and appropriate management strategies can lead to significantly improved outcomes. Despite considerable scientific and technological progress, a definitive cure for Parkinson’s disease has not yet been found. Nevertheless, the progressive course of PD highlights the critical need for early diagnosis and prompts therapeutic interventions to slow symptom advancement and enhance quality of life. In recent years, artificial intelligence (AI) has gained prominence as a powerful tool in various domains, including healthcare, where it holds significant promise for improving the diagnosis, treatment, and overall management of PD. This paper presents an in-depth exploration of the various ways AI can be applied in the diagnosis, therapeutic planning, and clinical management of Parkinson’s disease. AI-powered wearable devices, smartphone applications, machine learning (ML) algorithms, and natural language processing (NLP) technologies have demonstrated remarkable potential in facilitating early detection and real-time symptom monitoring in PD patients. Additionally, the integration of AI in PD management raises challenges, such as data privacy concerns and the need for extensive databases, to enhance diagnostic accuracy and treatment efficacy. This paper also explores these challenges, emphasizing the need for robust data security protocols and the development of large, reliable datasets to optimize AI applications in PD care.

Keywords: Parkinson’s disease (PD), neurodegenerative disorder, dopaminergic neurons, substantia nigra, motor symptoms, early diagnosis, therapeutic intervention, quality of life, artificial intelligence (AI)

[This article belongs to Research and Reviews: A Journal of Neuroscience ]

How to cite this article:
Gazal Rani. A Review on Applications of Artificial Intelligence (AI) in Parkinsons’s Disease Diagnosis and Treatment and Its Future Challenges. Research and Reviews: A Journal of Neuroscience. 2025; 15(03):1-15.
How to cite this URL:
Gazal Rani. A Review on Applications of Artificial Intelligence (AI) in Parkinsons’s Disease Diagnosis and Treatment and Its Future Challenges. Research and Reviews: A Journal of Neuroscience. 2025; 15(03):1-15. Available from: https://journals.stmjournals.com/rrjons/article=2025/view=233472


References

  1. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235–45.
  2. Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Neuron. 2003 Sep 11;39(6):889–909.
  3. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(Suppl 1):S3–S8.
  4. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368–76.
  5. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896–912.
  6. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013.
  7. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: A review. JAMA. 2014 Apr 23;311(16):1670–83.
  8. Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.
  9. Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, et al. The Parkinson’s progression markers initiative (PPMI) – establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018 Dec;5(12):1460–77.
  10. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Dec;30(12):1591–601.
  11. Radder DLM, de Vries NM, Riksen NP, van Nimwegen M, van der Linden A, MacNeil J, et al. Multidisciplinary care for people with Parkinson’s disease: The new kids on the block! Expert Rev Neurother. 2020 May;20(5):527–38.
  12. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019 Jan;25(1):24–9.
  13. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019 Jan;25(1):30–6.
  14. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc Neurol. 2017 Dec;2(4):230–43.
  15. Patel S, Khan Y, Lewkowicz D. Wearable technology and artificial intelligence: A promising partnership for Parkinson’s disease. Digit Health. 2021;7:1–13.
  16. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med. 2019 Jan;25(1):44–56.
  17. van der Schaar M, Yoon J, Jarrett D. Fundamental challenges in machine learning for time series in healthcare. Commun ACM. 2020 Jun;63(6):70–81.
  18. Carsten M, et al. Smart assistive technologies for Parkinson’s disease: Improving quality of life through AI. Neurodegener Dis Manag. 2019 Jun;9(3):155–68.
  19. Patel S, et al. Wearable devices for Parkinson’s disease: The role of AI in monitoring and management. J Parkinsons Dis. 2019;9(1):221–32.
  20. Sathyanarayana A, et al. Machine learning for early detection of Parkinson’s disease using structural MRI. Neuroimage Clin. 2017;16:111–7.
  21. Shamir L, et al. AI in the study of Parkinson’s disease: Applications in genetic and molecular research. Bioinformatics. 2017 Aug 1;33(15):2276–82.
  22. Xu Y, et al. Personalized treatment plans for Parkinson’s disease using AI: A review. Clin Neurol Neurosurg. 2018 Jan;172:70–7.
  23. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. N Engl J Med. 2018 Mar 15;378(11):981–3.
  24. Del Din S, et al. Analysis of free-living gait in older adults with and without Parkinson’s disease and with and without a history of falls: Identifying generic and disease-specific characteristics. J Gerontol A Biol Sci Med Sci. 2019 Mar;74(3):478–84.
  25. Farhan SMK, et al. Early diagnosis of Parkinson’s disease from structural MR images using deep learning techniques. J Med Imaging (Bellingham). 2019 Oct;6(4):044002.
  26. Guillemot V, et al. Barriers to the implementation of AI in healthcare: A systematic review. J Med Internet Res. 2018 Oct;20(10):e226.
  27. Mesko B. The guide to the future of medicine: Technology and the human touch. Budapest: Webicina; 2017.
  28. Brooks DJ, et al. Multi-modal data integration for Parkinson’s disease diagnosis and treatment: Challenges and opportunities. Front Neurosci. 2020;14:586.
  29. Ekins S, et al. Exploiting AI in drug discovery and development for Parkinson’s disease. Trends Pharmacol Sci. 2019 Aug;40(8):527–41.
  30. Floridi L, et al. AI4People—an ethical framework for a good AI society: Opportunities, risks, principles, and recommendations. Minds Mach. 2018 Dec;28(4):689–707.
  31. Li T, et al. Federated learning: Challenges, methods, and future directions. IEEE Signal Process Mag. 2020 May;37(3):50–60.
  32. Ravì D, et al. Predictive analytics in Parkinson’s disease using machine learning: A systematic review. J Biomed Inform. 2020 Feb;103:103388.
  33. Zhang L, et al. Digital therapeutics for Parkinson’s disease: AI-powered tools for improved patient outcomes. Digit Health. 2020;6:1–12.
  34. Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, et al. Technology in Parkinson’s disease: Challenges and opportunities. Mov Disord. 2016 Sep;31(9):1272–82.
  35. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Trans Biomed Eng. 2009 Apr;56(4):1015–22.
  36. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014 Sep;46(9):989–93.
  37. Scherfler C, Schocke M, Donnemiller E, Seppi K, Mair KJ, Poewe W. Imaging features of basal ganglia degeneration in Parkinson’s disease: An MR spectroscopy and PET study. J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):786–90.
  38. Armananzas R, et al. Predictive models of Parkinson’s disease progression using clinical and imaging data. J Biomed Inform. 2013 Oct;46(5):738–44.
  39. Del Din S, et al. Analysis of free-living gait in older adults with and without Parkinson’s disease and with and without a history of falls: Identifying generic and disease-specific characteristics. J Gerontol A Biol Sci Med Sci. 2016 Nov;71(11):1456–63.
  40. Kubota KJ, Chen JA, Little MA. Machine learning for large-scale wearable sensor data in Parkinson’s disease: Concepts, promises, pitfalls, and futures. Mov Disord. 2016 Sep;31(9):1314–26.
  41. Schwab P, et al. Deep learning-based prediction of Parkinson’s disease progression using clinical and neuroimaging data. NPJ Parkinsons Dis. 2018;4:17.
  42. IBM Watson Health: Transforming healthcare with AI. 2020 [cited 2025 Jun 30]. Available from: https://www.ibm.com/watson-health.
  43. Ravì D, Wong C, Deligianni F, Berthelot M, Andreu-Perez J, Lo B, et al. Deep learning for health informatics. IEEE J Biomed Health Inform. 2017 Jan;21(1):4–21.
  44. Pang MY, Yang Z, Zhang J, Lam FM, He CQ. Motor and cognitive training with an interactive robotic device for mobility function rehabilitation in older adults: A pilot feasibility study. J Neuroeng Rehabil. 2019;16(1):142.
  45. Patel S, Park H, Bonato P, Chan L, Rodgers M. A review of wearable sensors and systems with application in rehabilitation. J Neuroeng Rehabil. 2021;9:21.
  46. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019 May;1(5):206–15.
  47. Schwartz R, Dodge J, Smith NA, Etzioni O. Green AI. Commun ACM. 2020 Dec;63(12):54–63.
  48. McMahan HB, Moore E, Ramage D, Hampson S, y Arcas BA. Communication-efficient learning of deep networks from decentralized data. In: Artificial Intelligence and Statistics. PMLR; 2017. p. 1273–82.
  49. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019 Oct 25;366(6464):447–53.
  50. Sim I, Terry SF. The role of patient advocates in reducing clinical trial barriers. Nat Rev Drug Discov. 2020 May;19(5):307–8.
  51. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195.
  52. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017 May 30;69(21):2657–64.
  53. Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: A systematic review and meta-analysis. Lancet Digit Health. 2019 Dec;1(6):e271–87.
  54. Mesko B. The guide to the future of medicine: Technology and the human touch. Budapest: Webicina; 2018.
  55. S. Food and Drug Administration (FDA). Artificial intelligence and machine learning in software as a medical device. 2020 [cited 2025 Jun 30]. Available from: https://www.fda.gov.
  56. International Organization for Standardization (ISO). ISO/IEC JTC 1/SC 42 artificial intelligence. 2019 [cited 2025 Jun 30]. Available from: https://www.iso.org.
  57. Voigt P, Von dem Bussche A. The EU General Data Protection Regulation (GDPR): A practical guide. 1st ed. Cham: Springer International Publishing; 2017.
  58. Del Din S, Godfrey A, Mazza C, Lord S, Rochester L. Free-living monitoring of Parkinson’s disease: Lessons from the field. Mov Disord. 2019 Jun;34(6):936–43.
  59. Ekins S, Puhl AC, Zorn KM, Lane TR, Marino SB, Russo DP, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019 May;18(5):435–41.
  60. Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017 Dec;42:60–88.
  61. Gunning D, Stefik M, Choi J, Miller T, Stumpf S, Yang GZ. XAI—explainable artificial intelligence. Sci Robot. 2019 May;4(37):eaay7120.
  62. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017 Apr 20;18(1):83.
  63. Leung MKK, Delong A, Alipanahi B, Frey BJ. Machine learning in genomic medicine: A review of computational problems and data sets. Proc IEEE. 2016 Jan;104(1):176–97.
  64. Yang Q, Liu Y, Chen T, Tong Y. Federated machine learning: concept and applications. ACM Trans Intell Syst Technol. 2019 Mar;10(2):1–19.
  65. Chen JH, Asch SM. Machine learning and prediction in medicine—beyond the peak of inflated expectations. N Engl J Med. 2017 Jun 29;376(26):2507–9.
  66. Shah NH, Tenenbaum JD, Blayney DW. Translating clinical practice into the learning health system: lessons from the Palo Alto Medical Foundation. J Biomed Inform. 2019 Oct;97:103261.
Regular Issue Subscription Review Article
Volume 15
Issue 03
Received 27/05/2025
Accepted 02/07/2025
Published 05/12/2025
Publication Time 192 Days
72

Login


My IP

PlumX Metrics